TY - JOUR AU - Guo, C. AU - Manjili, M. H. AU - Subjeck, J. R. AU - Sarkar, D. AU - Fisher, P. B. AU - Wang, X. Y. PY - 2013 DA - 2013// TI - Therapeutic cancer vaccines: past, present, and future JO - Adv Cancer Res VL - 119 UR - https://doi.org/10.1016/B978-0-12-407190-2.00007-1 DO - 10.1016/B978-0-12-407190-2.00007-1 ID - Guo2013 ER - TY - JOUR AU - Fenoglio, D. a. n. i. e. l. a. AU - Traverso, P. a. o. l. o. AU - Parodi, A. l. e. s. s. i. a. AU - Kalli, F. r. a. n. c. e. s. c. a. AU - Zanetti, M. a. u. r. i. z. i. o. AU - Filaci, G. i. l. b. e. r. t. o. PY - 2013 DA - 2013// TI - Generation of more effective cancer vaccines JO - Human vaccines & immunotherapeutics VL - 9 UR - https://doi.org/10.4161/hv.26147 DO - 10.4161/hv.26147 ID - Fenoglio2013 ER - TY - JOUR AU - Sluis, T. C. AU - Sluijter, M. AU - Duikeren, S. AU - West, B. L. AU - Melief, C. J. AU - Arens, R. AU - Burg, S. H. AU - Hall, T. PY - 2015 DA - 2015// TI - Therapeutic peptide vaccine-induced CD8 T cells strongly modulate Intratumoral macrophages required for tumor regression JO - Cancer Immunol Res VL - 3 UR - https://doi.org/10.1158/2326-6066.CIR-15-0052 DO - 10.1158/2326-6066.CIR-15-0052 ID - Sluis2015 ER - TY - JOUR AU - Dubensky, T. W. AU - Reed, S. G. PY - 2010 DA - 2010// TI - Adjuvants for cancer vaccines JO - Semin Immunol VL - 22 UR - https://doi.org/10.1016/j.smim.2010.04.007 DO - 10.1016/j.smim.2010.04.007 ID - Dubensky2010 ER - TY - JOUR AU - Kastenmuller, K. AU - Wille-Reece, U. AU - Lindsay, R. W. AU - Trager, L. R. AU - Darrah, P. A. AU - Flynn, B. J. AU - Becker, M. R. AU - Udey, M. C. AU - Clausen, B. E. AU - Igyarto, B. Z. PY - 2011 DA - 2011// TI - Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets JO - J Clin Invest VL - 121 UR - https://doi.org/10.1172/JCI45416 DO - 10.1172/JCI45416 ID - Kastenmuller2011 ER - TY - JOUR AU - Kaczanowska, S. AU - Joseph, A. M. AU - Davila, E. PY - 2013 DA - 2013// TI - TLR agonists: our best frenemy in cancer immunotherapy JO - J Leukoc Biol VL - 93 UR - https://doi.org/10.1189/jlb.1012501 DO - 10.1189/jlb.1012501 ID - Kaczanowska2013 ER - TY - JOUR AU - Wang, L. AU - Smith, D. AU - Bot, S. AU - Dellamary, L. AU - Bloom, A. AU - Bot, A. PY - 2002 DA - 2002// TI - Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination JO - J Clin Invest VL - 110 UR - https://doi.org/10.1172/JCI0215536 DO - 10.1172/JCI0215536 ID - Wang2002 ER - TY - JOUR AU - Speiser, D. E. AU - Lienard, D. AU - Rufer, N. AU - Rubio-Godoy, V. AU - Rimoldi, D. AU - Lejeune, F. AU - Krieg, A. M. AU - Cerottini, J. C. AU - Romero, P. PY - 2005 DA - 2005// TI - Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909 JO - J Clin Invest VL - 115 UR - https://doi.org/10.1172/JCI23373 DO - 10.1172/JCI23373 ID - Speiser2005 ER - TY - JOUR AU - Valmori, D. AU - Souleimanian, N. E. AU - Tosello, V. AU - Bhardwaj, N. AU - Adams, S. AU - O'Neill, D. AU - Pavlick, A. AU - Escalon, J. B. AU - Cruz, C. M. AU - Angiulli, A. PY - 2007 DA - 2007// TI - Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming JO - Proc Natl Acad Sci U S A VL - 104 UR - https://doi.org/10.1073/pnas.0703395104 DO - 10.1073/pnas.0703395104 ID - Valmori2007 ER - TY - JOUR AU - Agrawal, S. AU - Zhao, Q. PY - 1998 DA - 1998// TI - Antisense therapeutics JO - Curr Opin Chem Biol VL - 2 UR - https://doi.org/10.1016/S1367-5931(98)80129-4 DO - 10.1016/S1367-5931(98)80129-4 ID - Agrawal1998 ER - TY - JOUR AU - Kurreck, J. PY - 2003 DA - 2003// TI - Antisense technologies. Improvement through novel chemical modifications JO - Eur J Biochem VL - 270 UR - https://doi.org/10.1046/j.1432-1033.2003.03555.x DO - 10.1046/j.1432-1033.2003.03555.x ID - Kurreck2003 ER - TY - JOUR AU - Pol, J. AU - Bloy, N. AU - Buque, A. AU - Eggermont, A. AU - Cremer, I. AU - Sautes-Fridman, C. AU - Galon, J. AU - Tartour, E. AU - Zitvogel, L. AU - Kroemer, G. PY - 2015 DA - 2015// TI - Trial watch: peptide-based anticancer vaccines JO - Oncoimmunology. VL - 4 UR - https://doi.org/10.4161/2162402X.2014.974411 DO - 10.4161/2162402X.2014.974411 ID - Pol2015 ER - TY - JOUR AU - Tan, A. C. AU - Goubier, A. AU - Kohrt, H. E. PY - 2015 DA - 2015// TI - A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial JO - J Immunother Cancer VL - 3 UR - https://doi.org/10.1186/s40425-015-0093-x DO - 10.1186/s40425-015-0093-x ID - Tan2015 ER - TY - STD TI - Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nat Med. 2013. ID - ref14 ER - TY - JOUR AU - Heeke, D. S. AU - Lin, R. AU - Rao, E. AU - Woo, J. C. AU - McCarthy, M. P. AU - Marshall, J. D. PY - 2016 DA - 2016// TI - Identification of GLA/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits JO - Vaccine. VL - 34 UR - https://doi.org/10.1016/j.vaccine.2016.04.012 DO - 10.1016/j.vaccine.2016.04.012 ID - Heeke2016 ER - TY - JOUR AU - Carlsson, G. AU - Gullberg, B. AU - Hafstrom, L. PY - 1983 DA - 1983// TI - Estimation of liver tumor volume using different formulas - an experimental study in rats JO - J Cancer Res Clin Oncol VL - 105 UR - https://doi.org/10.1007/BF00391826 DO - 10.1007/BF00391826 ID - Carlsson1983 ER - TY - JOUR AU - Rosalia, R. A. AU - Quakkelaar, E. D. AU - Redeker, A. AU - Khan, S. AU - Camps, M. AU - Drijfhout, J. W. AU - Silva, A. L. AU - Jiskoot, W. AU - Hall, T. AU - Veelen, P. A. PY - 2013 DA - 2013// TI - Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation JO - Eur J Immunol VL - 43 UR - https://doi.org/10.1002/eji.201343324 DO - 10.1002/eji.201343324 ID - Rosalia2013 ER - TY - JOUR AU - Bijker, M. S. AU - Eeden, S. J. AU - Franken, K. L. AU - Melief, C. J. AU - Offringa, R. AU - Burg, S. H. PY - 2007 DA - 2007// TI - CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity JO - J Immunol VL - 179 UR - https://doi.org/10.4049/jimmunol.179.8.5033 DO - 10.4049/jimmunol.179.8.5033 ID - Bijker2007 ER - TY - JOUR AU - Ohlschlager, P. AU - Spies, E. AU - Alvarez, G. AU - Quetting, M. AU - Groettrup, M. PY - 2011 DA - 2011// TI - The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA JO - Int J Cancer VL - 128 UR - https://doi.org/10.1002/ijc.25344 DO - 10.1002/ijc.25344 ID - Ohlschlager2011 ER - TY - JOUR AU - Goldinger, S. M. AU - Dummer, R. AU - Baumgaertner, P. AU - Mihic-Probst, D. AU - Schwarz, K. AU - Hammann-Haenni, A. AU - Willers, J. AU - Geldhof, C. AU - Prior, J. O. AU - Kundig, T. M. PY - 2012 DA - 2012// TI - Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients JO - Eur J Immunol VL - 42 UR - https://doi.org/10.1002/eji.201142361 DO - 10.1002/eji.201142361 ID - Goldinger2012 ER - TY - JOUR AU - Chang, L. S. AU - Leng, C. H. AU - Yeh, Y. C. AU - Wu, C. C. AU - Chen, H. W. AU - Huang, H. M. AU - Liu, S. J. PY - 2014 DA - 2014// TI - Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy JO - Mol Cancer VL - 13 UR - https://doi.org/10.1186/1476-4598-13-60 DO - 10.1186/1476-4598-13-60 ID - Chang2014 ER - TY - JOUR AU - Preville, X. AU - Ladant, D. AU - Timmerman, B. AU - Leclerc, C. PY - 2005 DA - 2005// TI - Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein JO - Cancer Res VL - 65 ID - Preville2005 ER - TY - JOUR AU - Duikeren, S. AU - Fransen, M. F. AU - Redeker, A. AU - Wieles, B. AU - Platenburg, G. AU - Krebber, W. J. AU - Ossendorp, F. AU - Melief, C. J. AU - Arens, R. PY - 2012 DA - 2012// TI - Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors JO - J Immunol VL - 189 UR - https://doi.org/10.4049/jimmunol.1201540 DO - 10.4049/jimmunol.1201540 ID - Duikeren2012 ER - TY - JOUR AU - Miles, A. P. AU - McClellan, H. A. AU - Rausch, K. M. AU - Zhu, D. AU - Whitmore, M. D. AU - Singh, S. AU - Martin, L. B. AU - Wu, Y. AU - Giersing, B. K. AU - Stowers, A. W. PY - 2005 DA - 2005// TI - Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations JO - Vaccine. VL - 23 UR - https://doi.org/10.1016/j.vaccine.2004.08.049 DO - 10.1016/j.vaccine.2004.08.049 ID - Miles2005 ER - TY - JOUR AU - Chianese-Bullock, K. A. AU - Pressley, J. AU - Garbee, C. AU - Hibbitts, S. AU - Murphy, C. AU - Yamshchikov, G. AU - Petroni, G. R. AU - Bissonette, E. A. AU - Neese, P. Y. AU - Grosh, W. W. PY - 2005 DA - 2005// TI - MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma JO - J Immunol VL - 174 UR - https://doi.org/10.4049/jimmunol.174.5.3080 DO - 10.4049/jimmunol.174.5.3080 ID - Chianese-Bullock2005 ER - TY - JOUR AU - Lawrence, G. W. AU - Saul, A. AU - Giddy, A. J. AU - Kemp, R. AU - Pye, D. PY - 1997 DA - 1997// TI - Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720 JO - Vaccine. VL - 15 UR - https://doi.org/10.1016/S0264-410X(96)00150-8 DO - 10.1016/S0264-410X(96)00150-8 ID - Lawrence1997 ER - TY - JOUR AU - Gregorio, E. AU - Caproni, E. AU - Ulmer, J. B. PY - 2013 DA - 2013// TI - Vaccine adjuvants: mode of action JO - Front Immunol VL - 4 UR - https://doi.org/10.3389/fimmu.2013.00214 DO - 10.3389/fimmu.2013.00214 ID - Gregorio2013 ER - TY - JOUR AU - Galli, G. AU - Medini, D. AU - Borgogni, E. AU - Zedda, L. AU - Bardelli, M. AU - Malzone, C. AU - Nuti, S. AU - Tavarini, S. AU - Sammicheli, C. AU - Hilbert, A. K. PY - 2009 DA - 2009// TI - Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels JO - Proc Natl Acad Sci U S A VL - 106 UR - https://doi.org/10.1073/pnas.0813390106 DO - 10.1073/pnas.0813390106 ID - Galli2009 ER - TY - STD TI - Hensel MT, Marshall JD, Dorwart MR, Heeke DS, Rao E, Tummala P, Yu L, Cohen GH, Eisenberg RJ, Sloan DD. Prophylactic herpes simplex virus 2 (HSV-2) vaccines Adjuvanted with stable emulsion and toll-like receptor 9 agonist induce a robust HSV-2-specific cell-mediated immune response, protect against symptomatic disease, and reduce the latent viral reservoir. J Virol. 2017;91. ID - ref29 ER - TY - JOUR AU - Behzad, H. AU - Huckriede, A. L. AU - Haynes, L. AU - Gentleman, B. AU - Coyle, K. AU - Wilschut, J. C. AU - Kollmann, T. R. AU - Reed, S. G. AU - McElhaney, J. E. PY - 2011 DA - 2011// TI - GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults JO - J Infect Dis VL - 205 UR - https://doi.org/10.1093/infdis/jir769 DO - 10.1093/infdis/jir769 ID - Behzad2011 ER - TY - STD TI - Fox CB, Moutaftsi M, Vergara J, Desbien AL, Nana GI, Vedvick TS, Coler RN, Reed SG. TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses. Vaccine. 2013. ID - ref31 ER - TY - JOUR AU - Misquith, A. AU - Fung, H. W. AU - Dowling, Q. M. AU - Guderian, J. A. AU - Vedvick, T. S. AU - Fox, C. B. PY - 2014 DA - 2014// TI - In vitro evaluation of TLR4 agonist activity: formulation effects JO - Colloids Surf B Biointerfaces VL - 113C UR - https://doi.org/10.1016/j.colsurfb.2013.09.006 DO - 10.1016/j.colsurfb.2013.09.006 ID - Misquith2014 ER - TY - JOUR AU - Baldwin, S. L. AU - Bertholet, S. AU - Kahn, M. AU - Zharkikh, I. AU - Ireton, G. C. AU - Vedvick, T. S. AU - Reed, S. G. AU - Coler, R. N. PY - 2009 DA - 2009// TI - Intradermal immunization improves protective efficacy of a novel TB vaccine candidate JO - Vaccine. VL - 27 UR - https://doi.org/10.1016/j.vaccine.2009.03.018 DO - 10.1016/j.vaccine.2009.03.018 ID - Baldwin2009 ER - TY - STD TI - de Cassan SC, Forbes EK, Douglas AD, Milicic A, Singh B, Gupta P, Chauhan VS, Chitnis CE, Gilbert SC, Hill AV, et al. The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by Prior immunization with a recombinant adenovirus. J Immunol. 2011. ID - ref34 ER - TY - JOUR AU - Song, Y. C. AU - Cheng, H. Y. AU - Leng, C. H. AU - Chiang, S. K. AU - Lin, C. W. AU - Chong, P. AU - Huang, M. H. AU - Liu, S. J. PY - 2014 DA - 2014// TI - A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity JO - J Control Release VL - 173 UR - https://doi.org/10.1016/j.jconrel.2013.10.027 DO - 10.1016/j.jconrel.2013.10.027 ID - Song2014 ER - TY - JOUR AU - Baumgaertner, P. AU - Jandus, C. AU - Rivals, J. P. AU - Derre, L. AU - Lovgren, T. AU - Baitsch, L. AU - Guillaume, P. AU - Luescher, I. F. AU - Berthod, G. AU - Matter, M. PY - 2012 DA - 2012// TI - Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells JO - Int J Cancer VL - 130 UR - https://doi.org/10.1002/ijc.26297 DO - 10.1002/ijc.26297 ID - Baumgaertner2012 ER -